List of Excipients in Branded Drug XYZAL ALLERGY 24HR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Chattem Inc	XYZAL ALLERGY 24HR	levocetirizine dihydrochloride	41167-3510	CELLULOSE, MICROCRYSTALLINE
Chattem Inc	XYZAL ALLERGY 24HR	levocetirizine dihydrochloride	41167-3510	HYPROMELLOSES
Chattem Inc	XYZAL ALLERGY 24HR	levocetirizine dihydrochloride	41167-3510	LACTOSE MONOHYDRATE
Chattem Inc	XYZAL ALLERGY 24HR	levocetirizine dihydrochloride	41167-3510	MAGNESIUM STEARATE
Chattem Inc	XYZAL ALLERGY 24HR	levocetirizine dihydrochloride	41167-3510	POLYETHYLENE GLYCOL 400

XYZAL Allergy 24HR Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

XYZAL Allergy 24HR is an over-the-counter levocetirizine product whose commercial value depends more on dosage-form differentiation, sensory performance, manufacturing efficiency, and retailer positioning than on active-ingredient exclusivity. The core 5 mg levocetirizine tablet is a mature product with limited standalone patent protection. The strongest commercial opportunities are in low-cost tablet platforms, orally disintegrating or chewable formats, liquid and softgel delivery, pediatric presentations, allergen-conscious excipient systems, and private-label supply.

What is XYZAL Allergy 24HR?

XYZAL Allergy 24HR contains levocetirizine dihydrochloride, an H1 antihistamine indicated for relief of allergy symptoms, including sneezing, runny nose, itchy or watery eyes, and nasal or throat itching. The standard adult and children six years and older dose is 5 mg once daily, with some patients responding to 2.5 mg daily [1].

The product is positioned as a once-daily, nonprescription allergy medicine. Its principal commercial competitors include cetirizine, loratadine, desloratadine, fexofenadine, diphenhydramine, and combination products containing an antihistamine with a decongestant.

Product characteristic	XYZAL Allergy 24HR
Active ingredient	Levocetirizine dihydrochloride
Common strength	5 mg
Primary dosage form	Immediate-release oral tablet
Regulatory category	OTC antihistamine
Typical adult dosing	One 5 mg tablet once daily
Key consumer claim	24-hour allergy relief
Main competitors	Zyrtec, Claritin, Allegra, Benadryl and store brands
Primary excipient opportunity	Cost, swallowability, stability, disintegration and format differentiation

What excipients are used in XYZAL Allergy 24HR tablets?

The exact inactive-ingredient profile depends on the marketed SKU, manufacturing site, country, and dosage form. U.S. product labeling identifies the product as an oral tablet containing inactive ingredients selected for compression, coating, stability, appearance, and handling [2].

Common excipient functions in levocetirizine immediate-release tablets include:

Excipient function	Typical material classes	Commercial purpose
Diluent	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Provides tablet mass and improves compressibility
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Supports granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Film former	Hypromellose	Provides tablet coating
Plasticizer	Polyethylene glycol or similar material	Improves coating flexibility
Opacifier or colorant	Titanium dioxide or approved color systems	Controls appearance and light protection

A manufacturer should not assume that an excipient listed for one XYZAL presentation applies to every product. Tablet, liquid, chewable, orally disintegrating, and softgel products generally require different inactive-ingredient systems.

How does excipient selection affect levocetirizine tablet performance?

Excipient selection affects four commercial attributes: dose uniformity, tablet robustness, dissolution, and consumer acceptance.

Compression and manufacturing

Levocetirizine 5 mg is a relatively low-dose product, so blend uniformity is important. A high-performing formulation needs adequate dilution and powder-flow control to prevent active-ingredient segregation. Direct compression can reduce process steps and cost, but it requires excipients with consistent particle size, density, and compactibility.

Microcrystalline cellulose can improve tablet strength and disintegration but may increase tablet size at a fixed dose. Lactose can support efficient compression and consumer familiarity, although lactose-free positioning may be commercially attractive. Co-processed excipients can reduce development time by combining filler, binder, and disintegration functions.

Disintegration and dissolution

The product is an immediate-release tablet. Rapid disintegration supports predictable dissolution and consumer perception, particularly when the tablet is taken without food or water. Excessive lubricant levels or prolonged blending can slow dissolution. A formulation that relies on a single disintegrant may be less robust across humidity and manufacturing-scale changes than a system using complementary disintegrant mechanisms.

Potential development targets include:

• Disintegration below the product’s established release specification.
• Consistent dissolution after accelerated stability storage.
• Lower tablet weight without compromising mechanical strength.
• Reduced sensitivity to lubricant overmixing.
• Improved performance under high humidity.

Swallowability

A 5 mg tablet can be made smaller, but smaller dimensions may increase friability or manufacturing sensitivity. Film coating can improve swallowability and mask taste, but it adds process time, coating-material cost, and weight.

The most practical route is often a compact, smooth, low-friction tablet using a thin film coat. A smaller tablet can support retailer claims such as "easy to swallow," although such claims require substantiation and careful label review.

Stability

Levocetirizine formulations must control moisture, light exposure, and excipient compatibility. Packaging is part of the stability strategy. Bottles with desiccants, high-barrier blister packs, and moisture-resistant coatings can reduce degradation risk but increase packaging cost.

Excipient suppliers can create value through:

• Low-moisture grades.
• Controlled particle-size distributions.
• Low-peroxide polymer systems.
• Improved coating barriers.
• Excipient combinations validated for hot and humid climates.

What excipient strategies can differentiate XYZAL from generic levocetirizine?

Because the active ingredient is mature, excipient differentiation is most valuable when it produces a measurable consumer or manufacturing benefit. A reformulation that merely changes a filler is unlikely to create durable market power.

Lactose-free and allergen-conscious tablets

A lactose-free tablet could address consumers who avoid lactose or prefer allergen-conscious products. This strategy would typically replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler.

The commercial benefit is greatest when the product also delivers a smaller tablet, cleaner label, or improved disintegration. A lactose-free claim must match the full formulation and manufacturing controls. Cross-contact and supplier documentation can affect the credibility of the claim.

Sugar-free chewable products

Mannitol, sorbitol, isomalt, and xylitol can support chewable formulations. Mannitol is often attractive because it provides cooling mouthfeel and relatively low hygroscopicity. Sorbitol can improve sweetness and mouthfeel but may increase moisture sensitivity and gastrointestinal tolerability concerns at higher exposure.

A chewable levocetirizine product could compete for consumers who dislike swallowing tablets. The main technical risks are taste masking, dose uniformity, friability, and moisture uptake.

Orally disintegrating tablets

An orally disintegrating tablet could offer water-free administration and portability. The formulation would require a fast-disintegrating matrix, controlled tablet hardness, low friability, and acceptable taste.

Key excipient classes include:

• Mannitol for mouthfeel and bulk.
• Crospovidone or croscarmellose sodium for rapid breakup.
• Flavor and sweetener systems for taste masking.
• Low-moisture binders and packaging barriers.
• Specialized compression aids for mechanical strength.

The commercial opportunity is strongest in travel, workplace, school, and on-the-go allergy use. The product would need to provide a meaningful consumer benefit over standard coated tablets, not only a new dosage-form description.

Liquid and pediatric formulations

A liquid levocetirizine product could target children and adults who cannot swallow tablets. Excipient design would focus on solubility, taste, preservative performance, viscosity, pH, and dosing accuracy.

Potential formulation components include:

• Purified water as the vehicle.
• Polyols or sugars for sweetness and viscosity.
• Buffer systems for pH control.
• Flavor and taste-masking agents.
• Preservatives where justified by the formulation and packaging.
• Chelating or antioxidant systems where compatible with stability requirements.

A sugar-free liquid could differentiate the product, but polyol selection must account for gastrointestinal tolerability. Unit-dose packaging could improve dosing accuracy and reduce multidose bottle contamination.

What formulation patents could protect an XYZAL-style product?

A new excipient system may be patentable only if it produces a non-obvious technical result and satisfies applicable patentability requirements. Levocetirizine itself is no longer a strong basis for new exclusivity in ordinary tablet products.

Potential claim areas include:

1. A specific levocetirizine-excipient ratio producing improved dissolution.
2. A low-moisture formulation with defined stability performance.
3. A taste-masked chewable or orally disintegrating composition.
4. A liquid formulation with defined pH, preservative, and solubility parameters.
5. A manufacturing process that improves content uniformity or reduces degradation.
6. A coated tablet with a defined barrier layer and dissolution profile.
7. A unit-dose delivery system that limits dosing error or contamination.

Patent strength depends on the claims, not the presence of a novel excipient alone. Broad claims covering standard materials such as mannitol, magnesium stearate, or microcrystalline cellulose are likely to face prior-art pressure. Narrow claims tied to measured performance, defined ratios, and validated stability data are more defensible.

What is the FDA regulatory status of XYZAL Allergy 24HR?

XYZAL Allergy 24HR is marketed in the United States as an OTC levocetirizine antihistamine. The product originated as a prescription product and later moved to nonprescription use following FDA review. FDA OTC labeling requires the active ingredient, purpose, warnings, directions, and inactive ingredients to be presented in the Drug Facts format [1, 3].

The primary regulatory pathways for a new excipient strategy are:

Product type	Likely regulatory route
Reformulated 5 mg tablet with conventional excipients	OTC drug application or applicable OTC pathway, depending on formulation and labeling
New liquid, chewable, or orally disintegrating product	FDA review may be required based on dosage form, formulation, and labeling differences
Private-label equivalent	Contract manufacturing and regulatory submission under the sponsor’s product pathway
Novel excipient or materially different delivery system	Greater FDA review burden and additional safety and quality documentation

A formulation change can affect dissolution, bioequivalence, stability, labeling, and manufacturing controls. A product cannot rely on an OTC monograph merely because the active ingredient is familiar if the dosage form or conditions of use fall outside the applicable regulatory framework.

How many patents protect XYZAL Allergy 24HR?

The commercial 5 mg OTC product is not principally protected by a current patent estate that would prevent ordinary generic or store-brand competition. Levocetirizine’s core composition and use patents are mature or expired in major markets. Product-level protection is more likely to arise from formulation, packaging, manufacturing, trademark, and trade-secret rights.

Protection category	Relevance to XYZAL Allergy 24HR
Active-ingredient patent	Limited for mature levocetirizine
Orange Book patent listing	Must be checked against the current FDA listing for the specific NDA
Method-of-use patent	Limited practical value for standard OTC allergy indications
Formulation patent	Potentially relevant for differentiated dosage forms
Manufacturing know-how	Relevant to cost, yield, stability, and scale-up
Trademark and trade dress	Important for branded shelf position
Regulatory exclusivity	Not the principal current barrier to generic entry

An Orange Book review should distinguish between the original prescription NDA and the current OTC product configuration. OTC products may have limited or no listed patent protection that materially restricts store-brand competition. Patent status should be verified in the current FDA Orange Book and applicable national registers before a launch or freedom-to-operate decision [4].

When does XYZAL lose exclusivity, and what generic entry risks exist?

The principal exclusivity risk has already shifted from patent expiry to ordinary OTC competition. Generic levocetirizine products, retailer brands, and private-label tablets can compete on price, count size, packaging, and distribution.

The main entry scenarios are:

1. A low-cost 5 mg immediate-release tablet that mirrors the established dosage form.
2. A retailer-branded levocetirizine product using a contract manufacturer.
3. A dual- or multi-pack sold during seasonal allergy periods.
4. A liquid or chewable product targeting pediatric or swallowing-sensitive consumers.
5. A combination product pairing levocetirizine with another allergy ingredient, subject to regulatory limits.

Paragraph IV litigation is less likely to be the central market issue for a mature OTC levocetirizine tablet than it would be for a patented prescription product. Any Paragraph IV analysis must be tied to a specific listed patent and ANDA or other abbreviated filing. No generic challenge should be inferred from the existence of a levocetirizine product alone.

Which companies can commercialize excipient-enabled alternatives?

The opportunity is open to branded consumer-health companies, generic manufacturers, contract development and manufacturing organizations, and excipient suppliers.

Generic and private-label manufacturers

These companies can compete through:

• Lower-cost direct compression.
• Retailer-specific pack sizes.
• Club-store multipacks.
• E-commerce bundles.
• Lactose-free or sugar-free claims.
• Seasonal inventory programs.
• Pediatric and water-free formats.

The strongest economic case is a formulation that lowers total cost of goods while preserving tablet appearance, dissolution, and shelf stability.

Excipient suppliers

Suppliers can pursue formulation partnerships using:

• Co-processed direct-compression excipients.
• Fast-disintegrating platforms.
• Taste-masking systems.
• Low-moisture excipients.
• Film-coating systems with improved barrier properties.
• Ready-to-use granulation blends.

The commercial model may include formulation licensing, preferred-supplier agreements, technical service, or supply contracts. A supplier’s defensibility improves when the formulation is supported by process parameters, analytical methods, and stability data rather than by a raw-material substitution alone.

Consumer-health brand owners

Brand owners can use excipient differentiation to support a premium SKU, but the claim must be visible and understandable. "Dissolves quickly," "easy to swallow," "sugar-free," or "water-free" generally has greater consumer value than an uncommunicated change in tablet filler.

How does XYZAL compare with competing antihistamines?

Product	Active ingredient	Typical commercial strength	Differentiation pressure
XYZAL	Levocetirizine	5 mg	Once-daily relief; tablet and alternative formats
Zyrtec	Cetirizine	10 mg	Broad brand recognition; liquid and chewable competition
Claritin	Loratadine	10 mg	Non-drowsy positioning; wide private-label presence
Allegra	Fexofenadine	180 mg	Non-drowsy positioning; multiple dosage forms
Benadryl	Diphenhydramine	Varies	Sedating antihistamine; strong legacy recognition

Levocetirizine competes in a crowded category where formulation attributes can influence purchase decisions. A new product must overcome strong retailer substitution and consumer familiarity with established brands.

What commercial opportunities are strongest?

The most credible opportunities are:

1. A smaller, lactose-free, film-coated 5 mg tablet with competitive cost.
2. A sugar-free chewable product with effective taste masking.
3. A water-free orally disintegrating tablet.
4. A pediatric liquid with accurate dosing and acceptable taste.
5. A private-label platform that supports multiple retailer pack sizes.
6. A low-moisture formulation optimized for blister packaging and e-commerce distribution.
7. A sustainable excipient and packaging system that reduces material use without impairing stability.

The best opportunity depends on whether the sponsor seeks premium pricing, retailer penetration, manufacturing margin, or licensing revenue. A conventional tablet has the lowest technical risk but also the weakest differentiation. An orally disintegrating or chewable product has greater commercial upside and greater formulation, packaging, and regulatory complexity.

Key Takeaways

• XYZAL Allergy 24HR is a mature OTC levocetirizine product with limited active-ingredient exclusivity.
• Excipients are most valuable as tools for dosage-form differentiation, manufacturing efficiency, taste masking, stability, and consumer claims.
• The most promising formats are chewable, orally disintegrating, liquid, pediatric, lactose-free, and sugar-free products.
• Standard filler substitution alone is unlikely to create durable patent protection.
• Formulation patents should focus on defined compositions linked to measurable stability, dissolution, taste, or manufacturing advantages.
• Generic and private-label competition is the main commercial threat to the standard 5 mg tablet.
• A successful excipient strategy must combine technical performance with a consumer-facing benefit and a cost model that supports retail pricing.

FAQs

Can levocetirizine be formulated without lactose?

Yes. Lactose can generally be replaced with materials such as microcrystalline cellulose, mannitol, dibasic calcium phosphate, or co-processed excipients, subject to formulation development, stability, dissolution, and regulatory review.

Is mannitol suitable for a levocetirizine chewable tablet?

Mannitol is a common candidate because it provides bulk, compressibility, and a cooling mouthfeel. The formulation still requires taste masking, moisture control, hardness optimization, and friability testing.

Can an excipient change create a new patent for XYZAL?

A change can support patent protection if the claimed composition or process is novel and non-obvious and produces a demonstrated technical effect. A routine substitution of one conventional filler for another is less likely to provide strong protection.

What packaging best supports a moisture-sensitive levocetirizine formulation?

High-barrier blister packaging or a tightly closed bottle with a desiccant can improve moisture control. The appropriate system depends on stability data, distribution conditions, package-opening behavior, and cost targets.

Is an OTC levocetirizine product eligible for private-label commercialization?

A private-label product can be commercialized through an appropriate FDA-compliant sponsor and manufacturing arrangement. The sponsor must establish the formulation, labeling, quality system, manufacturing controls, and applicable regulatory pathway.

References

1. U.S. Food and Drug Administration. (2021). Xyzal Allergy 24HR Drug Facts label.
2. DailyMed. (n.d.). Xyzal Allergy 24HR: Levocetirizine dihydrochloride tablet, film coated. National Library of Medicine.
3. U.S. Food and Drug Administration. (2017). FDA approves over-the-counter Xyzal Allergy 24HR for treatment of allergies.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.